Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 7/20 | 0.51 |
| ▸ | CCR3 | P51677 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154387 | 0.85 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL4966059 | 0.82 | HRH1 (0.56) | HRH1CCR3KCNH2 | |
| SCHEMBL5193030 | 0.82 | HRH1 (0.55) | HRH1CCR3KCNH2 | |
| Hydrochloric Acid SCHEMBL5192556 | 0.81 | HRH1 (0.54) | HRH1CCR3KCNH2 | |
| SCHEMBL187857 | 0.80 | HRH1 (0.66) | HRH1HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4969392 | 0.80 | HRH1 (0.56) | HRH1CCR3KCNH2OPRK1SLC6A4 | |
| SCHEMBL4969078 | 0.80 | HRH1 (0.52) | HRH1CCR3KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL1808272 | 0.78 | HRH1 (0.63) | HRH1HRH3SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL21071433 | 0.77 | HRH1 (0.61) | HRH1HRH3SLC6A4SLC6A2SLC6A3 | |
| Propionic Acid SCHEMBL6241250 | 0.76 | HRH1 (0.62) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625114-B1 | Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-20060264463-A1 | Chemical compounds | MEDTECH CONVERGENCE FUND, L.P. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264463-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.